asthma

Relovair, the Salford Lung Study, and the First “Real World” Trial Before Approval: A Breath of Fresh Air for Payers?

Earlier this month, GlaxoSmithKline (GSK) and a number of collaborators announced an innovative new study pertaining to Relovair, the company’s once-a-day combination of corticosteroid (fluticasone furoate) and long-acting beta agonist (vilanterol trifenatate), under development for the treatment of asthma and chronic obstructive pulmonary disorder (COPD). The year-long Salford Lung Study, anticipated to enrol around 4,000 … Continue reading »